Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 17/20 | 0.49 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.40 |
| ▸ | IDH1 | O75874 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL495835 | 0.90 | TRPV1 (0.52) | TRPV1IDH1 | |
| SCHEMBL496009 | 0.87 | TRPV1 (0.49) | TRPV1TRIM24IDH1 | |
| SCHEMBL495956 | 0.84 | TRPV1 (0.47) | TRPV1TRIM24 | |
| SCHEMBL496609 | 0.83 | TRPV1 (0.50) | TRPV1TRIM24 | |
| Hydrochloric Acid SCHEMBL496285 | 0.81 | TRPV1 (0.48) | TRPV1 | |
| SCHEMBL496012 | 0.80 | TRPV1 (0.49) | TRPV1 | |
| SCHEMBL496050 | 0.80 | TRPV1 (0.55) | TRPV1 | |
| Hydrochloric Acid SCHEMBL496711 | 0.79 | TRPV1 (0.49) | TRPV1 | |
| Hydrochloric Acid SCHEMBL495647 | 0.79 | TRPV1 (0.54) | TRPV1 | |
| Hydrochloric Acid SCHEMBL495723 | 0.79 | TRPV1 (0.49) | TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1955697-B1 | 2-AMINOBENZAMIDE DERIVATIVES AS VANILLOID RECEPTOR 1 (VR1) INHIBITORS USEFUL FOR THE TREATMENT OF PAIN OR BLADDER FUNCTION DISORDER | ASTELLAS PHARMA INC (JP) | 2012-05-02 | — | — | EP | disclosed |
| US-8106190-B2 | 2-aminobenzamide derivatives | ASTELLAS PHARMA INC. (JP) | 2012-01-31 | — | — | US | disclosed |
| US-20090233900-A1 | 2-AMINOBENZAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233900-A1 | 2-AMINOBENZAMIDE DERIVATIVE | TRPV1, TRPV2, TRPV5 | TRPV1 1/4885TRIM24 2531/4885IDH1 2005/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.